MedTrace Logo

Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia

NCT00585390 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2011-08-02

No results posted yet for this study

Summary

The purpose of this research study is to find out what effects (good and bad) that omega-3 fatty acids has on schizophrenia.

Conditions

Interventions

DIETARY_SUPPLEMENT

Omega-3 Fatty Acids

* Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams * Docosahexaenoic acid fish oil concentrate at 1.6 grams

OTHER

Olive oil placebo

Olive oil capsules, 8 capsules per day

DIETARY_SUPPLEMENT

EPA fish oil concentrate; DHA fish oil concentrate

3.2 grams for EPA 1.6 grams for DHA

DRUG

Placebo

Olive oil capsule

Sponsors & Collaborators

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Neil Richtand, MD · Unversity of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00585390 on ClinicalTrials.gov